S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61

Lumos Pharma Stock Forecast, Price & News

+0.08 (+1.10%)
(As of 06/24/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
6,049 shs
Average Volume
8,991 shs
Market Capitalization
$61.35 million
P/E Ratio
Dividend Yield
Price Target
30 days | 90 days | 365 days | Advanced Chart

Receive LUMO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lumos Pharma and its competitors with MarketBeat's FREE daily newsletter.

LUMO Stock Forecast (MarketRank)

Overall MarketRank

2.28 out of 5 stars

Medical Sector

294th out of 1,411 stocks

Pharmaceutical Preparations Industry

120th out of 672 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -
Lumos Pharma logo

About Lumos Pharma (NASDAQ:LUMO)

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.

LUMO Stock News Headlines

Lumos Pharma, Inc. Misses Q1 EPS by 3c
Lumos Pharma Q1 2022 Earnings Preview
Recap: Lumos Pharma Q4 Earnings
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
3 Analysts


Net Income
$-30.43 million
Pretax Margin


Sales & Book Value

Annual Sales
$230 thousand
Book Value
$10.65 per share


Free Float
Market Cap
$61.35 million
Not Optionable

Lumos Pharma Frequently Asked Questions

Should I buy or sell Lumos Pharma stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lumos Pharma in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Lumos Pharma stock.
View analyst ratings for Lumos Pharma
or view top-rated stocks.

What is Lumos Pharma's stock price forecast for 2022?

3 brokerages have issued 12 month price objectives for Lumos Pharma's shares. Their LUMO stock forecasts range from $25.00 to $35.00. On average, they expect Lumos Pharma's share price to reach $29.33 in the next year. This suggests a possible upside of 300.2% from the stock's current price.
View analysts' price targets for Lumos Pharma
or view top-rated stocks among Wall Street analysts.

How has Lumos Pharma's stock performed in 2022?

Lumos Pharma's stock was trading at $6.93 on January 1st, 2022. Since then, LUMO shares have increased by 5.8% and is now trading at $7.33.
View the best growth stocks for 2022 here

Are investors shorting Lumos Pharma?

Lumos Pharma saw a decline in short interest during the month of May. As of May 31st, there was short interest totaling 16,900 shares, a decline of 15.1% from the May 15th total of 19,900 shares. Based on an average trading volume of 13,000 shares, the short-interest ratio is currently 1.3 days. Approximately 0.4% of the shares of the company are sold short.
View Lumos Pharma's Short Interest

When is Lumos Pharma's next earnings date?

Lumos Pharma is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Lumos Pharma

How were Lumos Pharma's earnings last quarter?

Lumos Pharma, Inc. (NASDAQ:LUMO) released its earnings results on Thursday, August, 5th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.01) by $0.03. The company had revenue of $0.01 million for the quarter.
View Lumos Pharma's earnings history

Who are Lumos Pharma's key executives?

Lumos Pharma's management team includes the following people:
  • Mr. Richard J. Hawkins, CEO & Chairman (Age 73, Pay $950.32k)
  • Dr. John C. McKew Ph.D., Chief Scientific Officer & Pres (Age 58, Pay $804.98k)
  • Ms. Lori D. Lawley CPA, CFO & Principal Accounting Officer (Age 38, Pay $519.11k)
  • Lisa Miller, Sr. Director of Investor Relations
  • Mr. Bradley J. Powers J.D., Chief Compliance Officer & Gen. Counsel (Age 43)
  • Mr. Carl W. Langren, Consultant (Age 67)
  • Mr. Aaron Schuchart B.B.A., CPA, M.B.A., Chief Bus. Officer (Age 57)
  • Dr. David B. Karpf B.A., M.D., Chief Medical Officer (Age 67)
  • Mr. Eddie L. Varnado M.B.A., VP of Fin. & Corp. Controller

What other stocks do shareholders of Lumos Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Lumos Pharma investors own include Advanced Micro Devices (AMD), (NCLH), Northern Oil and Gas (NOG), Agilent Technologies (A), Air Lease (AL), Ampio Pharmaceuticals (AMPE), Bionano Genomics (BNGO), Chimerix (CMRX), Compagnie de Saint-Gobain (CODYY) and CorMedix (CRMD).

What is Lumos Pharma's stock symbol?

Lumos Pharma trades on the NASDAQ under the ticker symbol "LUMO."

Who are Lumos Pharma's major shareholders?

Lumos Pharma's stock is owned by many different retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (3.25%), BlackRock Inc. (0.71%), Private Advisor Group LLC (0.34%) and Concourse Financial Group Securities Inc. (0.00%). Company insiders that own Lumos Pharma stock include James E Flynn, John C Mckew, Kevin M Lalande and Kevin M Lalande.
View institutional ownership trends for Lumos Pharma

Which major investors are selling Lumos Pharma stock?

LUMO stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, and BlackRock Inc.. Company insiders that have sold Lumos Pharma company stock in the last two years include James E Flynn, and John C Mckew.
View insider buying and selling activity for Lumos Pharma
or view top insider-selling stocks.

Which major investors are buying Lumos Pharma stock?

LUMO stock was purchased by a variety of institutional investors in the last quarter, including Private Advisor Group LLC.
View insider buying and selling activity for Lumos Pharma
or or view top insider-buying stocks.

How do I buy shares of Lumos Pharma?

Shares of LUMO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lumos Pharma's stock price today?

One share of LUMO stock can currently be purchased for approximately $7.33.

How much money does Lumos Pharma make?

Lumos Pharma (NASDAQ:LUMO) has a market capitalization of $61.35 million and generates $230 thousand in revenue each year. The company earns $-30.43 million in net income (profit) each year or ($3.54) on an earnings per share basis.

How many employees does Lumos Pharma have?

Lumos Pharma employs 29 workers across the globe.

How can I contact Lumos Pharma?

Lumos Pharma's mailing address is 4200 MARATHON BLVD. SUITE 200, AUSTIN TX, 78756. The official website for Lumos Pharma is www.lumos-pharma.com. The company can be reached via phone at (512) 215-2630, via email at [email protected], or via fax at 515-296-3520.

This page (NASDAQ:LUMO) was last updated on 6/26/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.